Skip to main content

Conference Coverage

The 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium


J Clin Pathways. 2021;7(2):22-23.

Apalutamide Plus ADT Improves OS in Metastatic Castration-Sensitive Prostate Cancer

Among patients with metastatic castration-sensitive prostate cancer, apalutamide plus ADT improves OS with a significant reduction in risk of death.


Advanced Oral Therapy Adherence Among Patients With Prostate Cancer

Patients with prostate cancer who were non-adherent to advanced oral therapies experienced substantially higher HCRU than those who were adherent.


Apalutamide Plus Abiraterone Extends Radiographic PFS in Metastatic Castration-Resistant Prostate Cancer

Apalutamide added to abiraterone acetate plus prednisone improves radiographic PFS by 7.4 months vs abiraterone acetate plus prednisone alone in metastatic castration-resistant prostate cancer.


Real-World Cardiotoxicity of Abiraterone vs Enzalutamide for Prostate Cancer

Findings from a real-world study show abiraterone is associated with greater risk of cardiovascular-related hospitalizations among men with prostate cancer than enzalutamide.


Back to Top